Galmed Pharmaceuticals Ltd reports results for the quarter ended in March - Earnings Summary

Eocene

13/05/2021 18:29

* Galmed Pharmaceuticals Ltd  GLMD.OQ  reported a quarterly
adjusted loss of 38 cents​​ per share for the quarter ended
in March. The mean expectation of four analysts for the quarter
was for a loss of 39 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Galmed Pharmaceuticals Ltd's reported EPS for the quarter was
a loss of 38 cents​.
* The mean earnings estimate of analysts had fallen by
about 12.4% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* Galmed Pharmaceuticals Ltd shares had fallen by 28.9% this
quarter and lost 21.5% so far this year.
* The company reported a quarterly loss of $8.91 million.
* Wall Street's median 12-month price target for Galmed
Pharmaceuticals Ltd is $14.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 13 at 05:29 p.m. GMT.
​All figures in US dollars